ATE510841T1 - Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase - Google Patents

Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Info

Publication number: ATE510841T1
Authority: AT; Austria
Prior art keywords: disorders; kinase; thiazoliopyrimidines; phosphatidylinositol; kinase inhibitors
Prior art date: 2007-06-12

Application number

AT08762345T

Other languages

English (en)

Inventor

Timothy Hancox

Neil Pegg

Mandy Beswick

Toby Blench

Elsa Dechaux

Janusz Kulagowski

Alan Nadin

Stephen Price

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-12

Filing date

2008-06-12

Publication date

2011-06-15

2007-06-12 Priority claimed from GB0711344A external-priority patent/GB0711344D0/en

2007-08-10 Priority claimed from GB0715677A external-priority patent/GB0715677D0/en

2008-06-12 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2011-06-15 Application granted granted Critical

2011-06-15 Publication of ATE510841T1 publication Critical patent/ATE510841T1/de

Links

239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 3
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
-1 Thiazolopyrimidine compounds Chemical class 0.000 abstract 1
208000036142 Viral infection Diseases 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
230000006399 behavior Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000003915 cell function Effects 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000007368 endocrine function Effects 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000007102 metabolic function Effects 0.000 abstract 1
230000009385 viral infection Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

AT08762345T 2007-06-12 2008-06-12 Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase ATE510841T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0711344A GB0711344D0 (en)	2007-06-12	2007-06-12	Pharmaceutical compounds
GB0715677A GB0715677D0 (en)	2007-08-10	2007-08-10	Pharmaceutical compounds
PCT/GB2008/002014 WO2008152390A1 (en)	2007-06-12	2008-06-12	Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase

Publications (1)

Publication Number	Publication Date
ATE510841T1 true ATE510841T1 (de)	2011-06-15

Family

ID=39731164

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08762345T ATE510841T1 (de)	2007-06-12	2008-06-12	Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase

Country Status (7)

Country	Link
US (2)	US7893060B2 (de)
EP (1)	EP2158207B1 (de)
JP (1)	JP5539190B2 (de)
CN (1)	CN101679456B (de)
AT (1)	ATE510841T1 (de)
CA (1)	CA2692050A1 (de)
WO (1)	WO2008152390A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2916668B2 (ja)	1994-10-24	1999-07-05	三菱電線工業株式会社	ケーブル貫通部の防火構造
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
RU2423381C2 (ru)	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
NZ573646A (en)	2006-06-12	2012-04-27	Wyeth Llc	Single-chain multivalent binding proteins with effector function
US7893060B2 (en) *	2007-06-12	2011-02-22	F. Hoffmann-La Roche Ag	Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
EP2205242B1 (de)	2007-09-12	2015-04-15	Genentech, Inc.	Kombinationen von phosphoinositid-3-kinase-inhibitor-verbindungen und chemotherapeutischen mitteln und anwendungsverfahren
CA2704711C (en)	2007-09-24	2016-07-05	Genentech, Inc.	Thiazolopyrimidine p13k inhibitor compounds and methods of use
US20110230464A1 (en) *	2007-10-26	2011-09-22	Paul Goldsmith	Purine derivatives useful as p13 kinase inhibitors
AU2008343813B2 (en)	2007-12-19	2012-04-12	Amgen Inc.	Inhibitors of PI3 kinase
RU2531754C2 (ru)	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
CA2729045A1 (en)	2008-07-31	2010-02-04	Philippe Bergeron	Pyrimidine compounds, compositions and methods of use
TWI378933B (en)	2008-10-14	2012-12-11	Daiichi Sankyo Co Ltd	Morpholinopurine derivatives
WO2010103130A2 (en)	2009-03-13	2010-09-16	Katholieke Universiteit Leuven, K.U.Leuven R&D	Novel bicyclic heterocycles
US20120071475A1 (en)	2009-04-27	2012-03-22	Shionogi & Co., Ltd.	Urea derivatives having pi3k-inhibiting activity
US8158625B2 (en)	2009-05-27	2012-04-17	Genentech, Inc.	Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
BRPI1009022A2 (pt) *	2009-05-27	2016-03-08	Hoffmann La Roche	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
JP5579864B2 (ja)	2009-11-12	2014-08-27	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｎ−９−置換プリン化合物、組成物及び使用の方法
EP2499143B1 (de)	2009-11-12	2016-03-16	F.Hoffmann-La Roche Ag	N7-substituierte purin und pyrazolopyrimidin verbindungen, zusammensetzungen und verfahren zu ihrer verwendung
BR112012015827A2 (pt) *	2009-12-28	2016-12-06	Dcb Usa Llc	novos compostos de pirimidina como inibidores de mtor e p13k
GB201012889D0 (en)	2010-08-02	2010-09-15	Univ Leuven Kath	Antiviral activity of novel bicyclic heterocycles
WO2011159726A2 (en)	2010-06-14	2011-12-22	The Scripps Research Institute	Reprogramming of cells to a new fate
ES2536780T3 (es) *	2010-07-14	2015-05-28	F. Hoffmann-La Roche Ag	Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
GB201015411D0 (en)	2010-09-15	2010-10-27	Univ Leuven Kath	Anti-cancer activity of novel bicyclic heterocycles
TW201500358A (zh)	2010-12-16	2015-01-01	赫夫門羅氏藥廠股份有限公司	三環ｐｉ３ｋ抑制劑化合物及其使用方法
GB201119401D0 (en) *	2011-11-10	2011-12-21	Ucb Pharma Sa	Therapeutic agents
EP2790705B1 (de)	2011-12-15	2017-12-06	Novartis AG	Verwendung von inhibitoren der aktivität oder funktion von pi3k
KR20160027219A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
JP6109937B2 (ja)	2012-07-20	2017-04-05	クリーブバイオサイエンシズインコーポレイテッド	ｐ９７複合体の阻害剤としての融合ピリミジン
CN106232122A (zh) *	2013-09-27	2016-12-14	林伯士艾瑞斯公司	Irak抑制剂和其用途
GB201402431D0 (en) *	2014-02-12	2014-03-26	Karus Therapeutics Ltd	Compounds
US10294243B2 (en)	2014-06-05	2019-05-21	Bayer Cropscience Aktiengesellschaft	Bicyclic compounds as pesticides
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
KR101919189B1 (ko)	2016-02-18	2018-11-15	경북대학교 산학협력단	다중치환 4H-티아졸로[4,5-e][1,4]다이아제핀-5,8-다이온 유도체 및 이의 용도
CN116262758B (zh) *	2021-12-15	2025-02-28	上海博悦生物科技有限公司	7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE759493A (fr) *	1969-11-26	1971-05-25	Thomae Gmbh Dr K	Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
AT321295B (de)	1971-11-11	1975-03-25	Thomae Gmbh Dr K	Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
EP1028964A1 (de)	1997-11-11	2000-08-23	Pfizer Products Inc.	Thienopyrimidin- und thienopyridin-derivate als antikrebsmittel
BR0009338A (pt) *	1999-03-26	2001-12-26	Astrazeneca Ab	Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
BRPI0509799A (pt) *	2004-04-12	2007-11-13	Torrent Pharmaceuticals Ltd	2-propen-1-onas como indutores de hsp 70
GB0412467D0 (en) *	2004-06-04	2004-07-07	Astrazeneca Ab	Chemical compounds
GB0423653D0 (en) *	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
GB0508471D0 (en) *	2005-04-26	2005-06-01	Celltech R&D Ltd	Therapeutic agents
AU2006278627B2 (en)	2005-08-08	2011-08-18	Janssen Pharmaceutica, N.V.	Thiazolopyrimidine kinase inhibitors
TWI498332B (zh)	2006-04-26	2015-09-01	Hoffmann La Roche	作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
KR20090021155A (ko)	2006-04-26	2009-02-27	에프. 호프만-라 로슈 아게	Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
TW200801012A (en)	2006-04-26	2008-01-01	Piramed Ltd	Phosphoinositide 3-kinase inhibitor compounds and methods of use
WO2007129161A2 (en)	2006-04-26	2007-11-15	F. Hoffmann-La Roche Ag	Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
RU2470936C2 (ru)	2006-12-07	2012-12-27	Дженентек, Инк.	Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
MX2009005950A (es)	2006-12-07	2009-10-12	Genentech Inc	Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
WO2008152394A1 (en)	2007-06-12	2008-12-18	F.Hoffmann-La Roche Ag	Pharmaceutical compounds
US7893060B2 (en) *	2007-06-12	2011-02-22	F. Hoffmann-La Roche Ag	Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
CA2704711C (en)	2007-09-24	2016-07-05	Genentech, Inc.	Thiazolopyrimidine p13k inhibitor compounds and methods of use

2008
- 2008-06-12 US US12/663,823 patent/US7893060B2/en not_active Expired - Fee Related
- 2008-06-12 CN CN2008800196804A patent/CN101679456B/zh not_active Expired - Fee Related
- 2008-06-12 JP JP2010511720A patent/JP5539190B2/ja not_active Expired - Fee Related
- 2008-06-12 WO PCT/GB2008/002014 patent/WO2008152390A1/en not_active Ceased
- 2008-06-12 EP EP08762345A patent/EP2158207B1/de not_active Not-in-force
- 2008-06-12 AT AT08762345T patent/ATE510841T1/de not_active IP Right Cessation
- 2008-06-12 CA CA002692050A patent/CA2692050A1/en not_active Abandoned
2011
- 2011-01-07 US US12/986,317 patent/US8168633B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP5539190B2 (ja)	2014-07-02
EP2158207B1 (de)	2011-05-25
US20110098270A1 (en)	2011-04-28
EP2158207A1 (de)	2010-03-03
CN101679456B (zh)	2012-09-05
US7893060B2 (en)	2011-02-22
CA2692050A1 (en)	2008-12-18
US20100190769A1 (en)	2010-07-29
CN101679456A (zh)	2010-03-24
WO2008152390A1 (en)	2008-12-18
JP2010529182A (ja)	2010-08-26
US8168633B2 (en)	2012-05-01

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE510841T1 (de)	2011-06-15	Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
DE602008004650D1 (de)	2011-03-03	Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
MX2009010881A (es)	2009-12-14	Compuestos farmaceuticos.
MX2009010884A (es)	2009-12-14	2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
GB0423653D0 (en)	2004-11-24	Pharmaceutical compounds
ATE549336T1 (de)	2012-03-15	Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
MX2008013578A (es)	2009-03-23	Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
WO2008036308A3 (en)	2008-05-08	Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
ATE543819T1 (de)	2012-02-15	Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
MX2010002820A (es)	2010-04-01	Analogos de tiazolidindiona para tratamiento de hipertension.
UY30323A1 (es)	2007-10-31	Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
WO2009011850A3 (en)	2009-03-05	Novel therapeutic compounds
NO20070484L (no)	2007-03-26	Sammenspleisede pyrimidinderivater og sammensetninger derav som CXCR3 reseptormodulatorer, anvendbare ved forebygging og behandling av inflammatoriske og immunregulatoriske lidelser og sykdommer.
EA200802329A1 (ru)	2009-06-30	Производные триазола ii
WO2007084391A3 (en)	2008-03-20	Thiazole compounds as protein kinase b ( pkb) inhibitors
TNSN08227A1 (en)	2009-10-30	[4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.
NO20084845L (no)	2009-02-03	2-pyrazinonderivater for behandling av sykdom eller tilstander der inhibiering av neutrofil elastaseaktivitetet er gunstig
NO20070655L (no)	2007-03-21	2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20084872L (no)	2009-02-03	2-pyridonderivater for behandling av sykdom eller tilstander der inhibering av neutrofil elastaseaktivitet er gunstig
ATE537830T1 (de)	2012-01-15	Nicotinamid derivate und ihre verwendung als therapeutika
SE0301232D0 (sv)	2003-04-25	Novel use
ATE435223T1 (de)	2009-07-15	Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2010008226A (es)	2010-10-25	Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
EA200900913A1 (ru)	2009-12-30	Производное триазола в качестве ингибитора hsp90
ECSP099046A (es)	2009-02-27	Derivados ciclopropil amina